Clinical trial

Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer

NCT05430399

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention utidelone Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record docetaxel Normalized identity: docetaxelView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2022-06-21

PhasePHASE3

Conditions

Breast Neoplasmsunresolved

Locally Advanced or Metastatic Breast Cancerunresolved

Interventions

utideloneDRUG

docetaxelDRUG · verified · RxNorm: docetaxel

Sponsors & collaborators

Sun Yat-sen Universitylead sponsor

Beijing Biostar Pharmaceuticals Co., Ltd.collaborator

Hunan Cancer Hospitalcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05430399 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.